Crinetics Pharmaceuticals (CRNX) shares were down more than 12% Friday after the company reported positive topline results from a phase 2 trial of investigational compound atumelnant for treating classic congenital adrenal yyperplasia, or CAH, and adrenocorticotropic hormone, or ACTH-dependent Cushing's syndrome.
The study, which included 28 patients across three dose groups, showed significant and statistically meaningful reductions in key biomarkers, with a mean reduction of up to 80% in androstenedione, the pharmaceutical company said, adding that atumelnant was generally well-tolerated, with no severe treatment-related adverse events or discontinuations.
The trial demonstrated improvements in CAH symptoms, including testosterone normalization in most female participants, a consistent decrease in total adrenal volume, and the resolution of androgen-mediated polycythemia in the majority of affected participants, the company said.
Price: 42.64, Change: -5.87, Percent Change: -12.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.